Beta Bionics Inc BBNX

$18.96 +0.09 (0.48%)

Valuation

Market cap
848,961,000
Revenue TTM
$100,250,000
Net income TTM
$-73,200,000
PE ratio
0.00
Forward PE
—
Profit margin
-73.02%
Debt to equity
0.00

Trading

Volume
515,000
Avg volume
1,360,900
Day's range
$18.27 – $19.26
Shares out
44,990,000
Stochastic %K
13%
Beta
3.39
Analysts
Strong Sell
Price target
$22.57

Price

Company profile

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin...

Show more

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.

Industry
Medical Devices
Sector
Healthcare
Phone
949 427 7785
Website
https://www.betabionics.com
Address
11 Hughes, Irvine, United States

Latest news

No headlines yet.